participants in the study Management Information System (MIS).

Annual Burden Estimates

The following table provides the combined burden estimates for the

previously-approved field data collection instrument, and the current request. Burden for all instruments is annualized over three years.

Activity/respondent	Annual number of respondents	Number of responses per respondent	Average burden per response (minutes)	Total annual burden hours
Collection of Field Data (Approved April 20, 2012)				
Selecting Study Grantees Discussions/grantee and partner organization staff	50	1	60	50
Introductory Script and Baseline Survey (Currently Requested)				
Introductory Script: (1) Grantee staff (2) Program applicants Baseline Survey: (1) Study participants	30 2,105 2,000	70.2 1 1	10 10 30	351 351 1.000
Study MIS (Currently Requested)				
Study MIS: (1) Grantee staff	30	2,517	2	2,517

Estimated Total Annual Burden Hours: 4.269.

Additional Information

Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Planning, Research, and Evaluation, 370 L'Enfant Promenade SW., Washington, DC 20447, Attn: OPRE Reports Clearance Officer. All requests should be identified by the title of the information collection. Email address: OPREinfocollection@acf. hhs.gov.

OMB Comment

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Email: OIRA SUBMISSION@OMB.E0P.GOV, Attn: Desk Officer for the Administration for Children and Families.

Steven M. Hanmer,

Reports Clearance, Officer. [FR Doc. 2012–15440 Filed 6–26–12; 8:45 am]

BILLING CODE 4184-37-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0747]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Waivers of In Vivo Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form and Type A Medicated Articles

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Waivers of In Vivo Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form and Type A Medicated Articles" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Juanmanuel Vilela, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50–400B, Rockville, MD 20850, 301– 796–7651,

Juanmanuel. Vilela@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: On March 19, 2012, the Agency submitted a proposed collection of information entitled "Waivers of In Vivo Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form and Type A Medicated

Articles" to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0575. The approval expires on June 30, 2015. A copy of the supporting statement for this information collection is available on the Internet at http://www.reginfo.gov/public/do/PRAMain.

Dated: June 20, 2012.

Leslie Kux,

Assistant Commissioner for Policy. [FR Doc. 2012–15721 Filed 6–26–12; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0357]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Device Decision Analysis: A Risk-Tolerance Pilot Study

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the